ZTS Stock: Price, Earnings History and SEC Filings
Zoetis Inc. (ZTS) last traded at $79.72, up 1.17% on the latest session and up 14.2% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $1.87 against an analyst estimate of $1.84, a beat of 1.6%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
ZTS earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 6, 2026 | $1.87 | $1.84 | +1.63% |
| Mar 2026 | May 7, 2026 | $1.53 | $1.61 | -4.97% |
| Dec 2025 | Feb 12, 2026 | $1.48 | $1.40 | +5.71% |
| Sep 2025 | Nov 4, 2025 | $1.70 | $1.62 | +4.94% |
ZTS beat the analyst EPS estimate in 3 of its last 4 reported quarters. Source: Nasdaq.
How ZTS reacts to earnings
Across its last 8 earnings releases, ZTS moved 7.4% on average the next session, in either direction. It rose after 1 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-06 | Before open | +3.87% |
| 2026-05-07 | Before open | -21.50% |
| 2026-02-12 | Before open | -2.35% |
| 2025-11-04 | Before open | -13.78% |
| 2025-08-05 | Before open | -3.75% |
| 2025-05-06 | Before open | -5.18% |
| 2025-02-13 | Before open | -5.15% |
| 2024-11-04 | Before open | -3.72% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
ZTS financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $9.5B | $2.7B | $2.3B | 28.2% | $6.02 |
| 2024 | $9.3B | $2.5B | $2.3B | 26.9% | $5.47 |
| 2023 | $8.5B | $2.3B | $1.6B | 27.4% | $5.07 |
| 2022 | $8.1B | $2.1B | $1.3B | 26.2% | $4.49 |
| 2021 | $7.8B | $2.0B | $1.7B | 26.2% | $4.27 |
| 2020 | $6.7B | $1.6B | $1.7B | 24.5% | $3.42 |
| 2019 | $6.3B | $1.5B | $1.3B | 24.0% | $3.11 |
| 2018 | $5.8B | $1.4B | $1.5B | 24.5% | $2.93 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for ZTS
- 8-K · Oct 13, 2026Officer or director change, Regulation FD disclosure, Financial statements and exhibits
- 8-K · Oct 8, 2026Regulation FD disclosure, Financial statements and exhibits
- 8-K · Aug 6, 2026Officer or director change, Financial statements and exhibits
- 10-Q · Aug 6, 2026
- 8-K · Aug 6, 2026Results of operations, Financial statements and exhibits
- 8-K · May 22, 2026Officer or director change, Shareholder vote
- 8-K · May 20, 2026Regulation FD disclosure, Financial statements and exhibits
- 10-Q · May 7, 2026
- 8-K · May 7, 2026Results of operations, Financial statements and exhibits
- DEF 14A · Apr 8, 2026
Insider filing activity
ZTS insiders filed 12 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
ZTS news
- Zoetis stock trades at EUR 71.24 ahead of Q3 resultsNov 1, 2026 · ad-hoc-news.de
- IDEXX Laboratories Reports Soon: How Has The Stock Reacted To Past Earnings?Oct 30, 2026 · trefis.com
- Zoetis (ZTS) Ascends While Market Falls: Some Facts to NoteOct 29, 2026 · finance.yahoo.com
- Michael Burry Portfolio: Top 5 Stock PicksOct 29, 2026 · finance.yahoo.com
- Zoetis (ZTS) vs. IDXX and ELAN: Is Valuation Compression Creating a Rare Opportunity in Animal Health?Oct 29, 2026 · finance.yahoo.com
- Zoetis (ZTS) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseOct 29, 2026 · finance.yahoo.com
- Zoetis (ZTS) Wins FDA Approval For Convenia RTU, Is The Undervaluation Case Still Intact?Oct 29, 2026 · finance.yahoo.com
- FDA approves Convenia RTU ahead of Q3 results for Zoetis stockOct 29, 2026 · ad-hoc-news.de
About Zoetis Inc.
Zoetis Inc. (ZTS) is a US-listed public company on NYSE. The SEC classifies its business as Pharmaceutical Preparations. Its fiscal year ends in December.